Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Is there potential for the approval of monoclonal antibodies to treat thyroid-associated ophthalmopathy?

Literature DB >> 31662952

Is there potential for the approval of monoclonal antibodies to treat thyroid-associated ophthalmopathy?

Terry J Smith¹.

Abstract

Entities: Chemical Disease Gene Species

Keywords: Autoimmune; Graves’ disease; Insulin-like growth factor-I receptor; Monoclonal antibody

Year: 2018 PMID： 31662952 PMCID： PMC6818270 DOI： 10.1080/21678707.2018.1521268

Source DB: PubMed Journal: Expert Opin Orphan Drugs ISSN： 2167-8707 Impact factor: 0.694

× No keyword cloud information.

31 in total

1. Immunoglobulins from patients with Graves' disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor.

Authors: Terry J Smith; Neil Hoa
Journal: J Clin Endocrinol Metab Date: 2004-10 Impact factor: 5.958

Review 2. Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy.

Authors: Terry J Smith; Joseph A M J L Janssen
Journal: Endocr Rev Date: 2019-02-01 Impact factor: 19.871

Review 3. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.

Authors: Robert J Moots; Cinzia Curiale; Danielle Petersel; Catherine Rolland; Heather Jones; Eduardo Mysler
Journal: BioDrugs Date: 2018-06 Impact factor: 5.807

Review 4. Graves' Disease.

Authors: Terry J Smith; Laszlo Hegedüs
Journal: N Engl J Med Date: 2016-10-20 Impact factor: 91.245

5. Teprotumumab for Thyroid-Associated Ophthalmopathy.

Authors: Terry J Smith; George J Kahaly; Daniel G Ezra; James C Fleming; Roger A Dailey; Rosa A Tang; Gerald J Harris; Alessandro Antonelli; Mario Salvi; Robert A Goldberg; James W Gigantelli; Steven M Couch; Erin M Shriver; Brent R Hayek; Eric M Hink; Richard M Woodward; Kathleen Gabriel; Guido Magni; Raymond S Douglas
Journal: N Engl J Med Date: 2017-05-04 Impact factor: 91.245

6. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study.

Authors: Mario Salvi; Guia Vannucchi; Nicola Currò; Irene Campi; Danila Covelli; Davide Dazzi; Simona Simonetta; Claudio Guastella; Lorenzo Pignataro; Sabrina Avignone; Paolo Beck-Peccoz
Journal: J Clin Endocrinol Metab Date: 2014-12-15 Impact factor: 5.958

7. Detection of TSH receptor RNA in cultured fibroblasts from patients with Graves' ophthalmopathy and pretibial dermopathy.

Authors: A E Heufelder; C M Dutton; G Sarkar; K A Donovan; R S Bahn
Journal: Thyroid Date: 1993 Impact factor: 6.568

8. Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes.

Authors: Hong Chen; Tünde Mester; Nupur Raychaudhuri; Courtney Y Kauh; Shivani Gupta; Terry J Smith; Raymond S Douglas
Journal: J Clin Endocrinol Metab Date: 2014-05-30 Impact factor: 5.958

9. Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor I receptor pathway.

Authors: Jane Pritchard; Rui Han; Noah Horst; William W Cruikshank; Terry J Smith
Journal: J Immunol Date: 2003-06-15 Impact factor: 5.422